Dr. Mark Thursz

Biography

Mark Thursz is a Professor of Hepatology at Imperial College London and a consultant in hepatology at St Mary's Hospital, London. His clinical interests encompass viral hepatitis, alcoholic liver disease, and fatty liver disease. He is currently focused on developing treatment programs for chronic hepatitis B infection in resource-poor settings to reduce the risk of hepatocellular carcinoma. Professor Thursz's research interests revolve around the natural history of viral hepatitis and fatty liver disease, examining the factors that determine chronic infection and the progression of liver disease. He has a special interest in the genetic determinants of disease outcomes, employing genetic association and genome-wide scanning techniques to identify causative variants. He is the chief investigator of multi-centre trials, including the WAFT-C trial, which studies warfarin anticoagulation in liver fibrosis patients who have undergone transplantation for hepatitis C, and the STOPAH trial, which investigates steroids and pentoxifylline in alcoholic hepatitis. Furthermore, Professor Thursz serves as the secretary of the British Association for the Study of Liver (BASL) and currently holds the vice-secretary position in the European Association for the Study of Liver, with a special responsibility for EU policy advocacy in Brussels.

Research Interests

Experience